How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia? - PubMed (original) (raw)
Review
. 2017 Dec;37(4):787-802.
doi: 10.1016/j.cll.2017.07.004. Epub 2017 Sep 28.
Affiliations
- PMID: 29128069
- DOI: 10.1016/j.cll.2017.07.004
Review
How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?
Jie Xu et al. Clin Lab Med. 2017 Dec.
Abstract
Multicolor flow cytometry (MFC), combined with molecular and cytogenetic studies, is the most common method for detecting minimal residual disease (MRD) in acute myeloid leukemia (AML). Studies have shown that a positive MFC MRD study after induction and/or consolidation, or before allogeneic hematopoietic stem cell transplantation, correlates with risk of relapse and inferior survival. However, there is little information on technical and analytical details. This article shares the authors' experience using MFC for AML MRD detection, including antibody panel design, data analysis, and interpretation. It summarizes diagnostic pearls and pitfalls, and provides practical information for pathologists or hematologists.
Keywords: Acute myeloid leukemia; Minimal residual disease; Multicolor flow cytometry.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
- Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Getta BM, Devlin SM, Levine RL, Arcila ME, Mohanty AS, Zehir A, Tallman MS, Giralt SA, Roshal M. Getta BM, et al. Biol Blood Marrow Transplant. 2017 Jul;23(7):1064-1071. doi: 10.1016/j.bbmt.2017.03.017. Epub 2017 Mar 15. Biol Blood Marrow Transplant. 2017. PMID: 28315400 Free PMC article. - The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z, Guo M, Zhang Y, Xu S, Cheng H, Wu J, Zhang W, Hu X, Yang J, Wang J, Tang G. Wang Z, et al. Int J Lab Hematol. 2019 Oct;41(5):607-614. doi: 10.1111/ijlh.13070. Epub 2019 Jun 4. Int J Lab Hematol. 2019. PMID: 31162830 - Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M, Perez-Corral A, Martínez-Laperche C, Bento L, Pascual C, Kwon M, Balsalobre P, Muñoz C, Buces E, Serrano D, Gayoso J, Buño I, Anguita J, Diéz-Martín JL. Bastos-Oreiro M, et al. Eur J Haematol. 2014 Sep;93(3):239-46. doi: 10.1111/ejh.12336. Epub 2014 Apr 29. Eur J Haematol. 2014. PMID: 24702162 - The role of multiparameter flow cytometry for disease monitoring in AML.
Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. Kern W, et al. Best Pract Res Clin Haematol. 2010 Sep;23(3):379-90. doi: 10.1016/j.beha.2010.06.007. Epub 2010 Aug 12. Best Pract Res Clin Haematol. 2010. PMID: 21112037 Review. - Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Dominietto A. Dominietto A. Curr Opin Hematol. 2011 Nov;18(6):381-7. doi: 10.1097/MOH.0b013e32834bac7d. Curr Opin Hematol. 2011. PMID: 21986564 Review.
Cited by
- Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.
Zhao L, Yang J, Chen M, Xiang X, Ma H, Niu T, Gong Y, Chen X, Liu J, Wu Y. Zhao L, et al. Ann Hematol. 2024 Apr;103(4):1197-1209. doi: 10.1007/s00277-024-05646-7. Epub 2024 Feb 8. Ann Hematol. 2024. PMID: 38329487 - Improved YOLOv7 Algorithm for Detecting Bone Marrow Cells.
Cheng Z, Li Y. Cheng Z, et al. Sensors (Basel). 2023 Sep 3;23(17):7640. doi: 10.3390/s23177640. Sensors (Basel). 2023. PMID: 37688095 Free PMC article. - Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2-mutated acute myeloid leukemia.
Tatarian J, Tupper N, Li P, Feusier J, Abdo M, Hyter S, Gonzales PR, Zhang D, Woodroof J, Kelting S, Godwin AK, Cui W. Tatarian J, et al. Am J Clin Pathol. 2023 Nov 2;160(5):490-499. doi: 10.1093/ajcp/aqad077. Am J Clin Pathol. 2023. PMID: 37458189 Free PMC article. - Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial.
Suo X, Zheng F, Wang D, Zhao L, Liu J, Li L, Zhang Z, Zhang C, Li Y, Yang S, Zhao X, Shi R, Wu Y, Jiao Z, Song J, Zhang L, Lu X, Yuan L, Gao S, Zhang J, Zhao X, Bai G, Liu K, Mi Y. Suo X, et al. Exp Hematol Oncol. 2023 May 12;12(1):45. doi: 10.1186/s40164-023-00409-y. Exp Hematol Oncol. 2023. PMID: 37173750 Free PMC article. - Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.
Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, Lin D, Chen Y, Xiao J, Sun Z, Deng L, Liang X, Zhang H, Guo Z, Dai M, Shi P, Huang F, Fan Z, Yin Z, Xuan L, Lin R, Jiang X, Yu G, Liu Q. Jin H, et al. J Hematol Oncol. 2023 Apr 29;16(1):42. doi: 10.1186/s13045-023-01437-1. J Hematol Oncol. 2023. PMID: 37120593 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical